Penn. paying for counter-detailing
“If you just practice smart, you'll be able to give better care and, by the way, save money,” Avorn said. He first developed an academic detailing program 25 years ago while in medical school.
The agency denied Pain Therapeutics' and Durect's abuse-deterrent opioid in a complete response letter after warning the drugmakers about how they promoted the drug.
The OPDP sent its second untitled letter this week, this time to Durect and Pain Therapeutics over the presentation of Remoxy ER.
The regulator cited inconsistencies with how safety trial data was recorded in a report released ahead of the advisory committee's meeting on Wednesday.